Ivermectin Treatment of Patients with Severe Ocular Onchocerciasis

H. R. Taylor Johns Hopkins University, Baltimore, Maryland; Case Western Reserve University and University Hospitals, Cleveland, Ohio

Search for other papers by H. R. Taylor in
Current site
Google Scholar
PubMed Close
,
R. D. Semba Johns Hopkins University, Baltimore, Maryland; Case Western Reserve University and University Hospitals, Cleveland, Ohio

Search for other papers by R. D. Semba in
Current site
Google Scholar
PubMed Close
,
H. S. Newland Johns Hopkins University, Baltimore, Maryland; Case Western Reserve University and University Hospitals, Cleveland, Ohio

Search for other papers by H. S. Newland in
Current site
Google Scholar
PubMed Close
,
E. Keyvan-Larijani Johns Hopkins University, Baltimore, Maryland; Case Western Reserve University and University Hospitals, Cleveland, Ohio

Search for other papers by E. Keyvan-Larijani in
Current site
Google Scholar
PubMed Close
,
A. White Johns Hopkins University, Baltimore, Maryland; Case Western Reserve University and University Hospitals, Cleveland, Ohio

Search for other papers by A. White in
Current site
Google Scholar
PubMed Close
,
Z. Dukuly Johns Hopkins University, Baltimore, Maryland; Case Western Reserve University and University Hospitals, Cleveland, Ohio

Search for other papers by Z. Dukuly in
Current site
Google Scholar
PubMed Close
, and
B. M. Greene Johns Hopkins University, Baltimore, Maryland; Case Western Reserve University and University Hospitals, Cleveland, Ohio

Search for other papers by B. M. Greene in
Current site
Google Scholar
PubMed Close
DOI:
https://doi.org/10.4269/ajtmh.1989.40.494
Volume/Issue:
Volume 40: Issue 5
Page(s):
494–500
Restricted access
Get Permissions

The treatment of onchocerciasis with diethylcarbamazine and suramin is associated with an exacerbation of ocular disease. This occurs more frequently in patients with severe onchocercal ocular disease. We assessed ocular changes following ivermectin treatment in 39 patients with severe ocular onchocerciasis. Patients were treated with 100, 150, or 200 µg/kg of ivermectin at either 1 or 2 year intervals and followed for 3 years. There was no evidence for an acute exacerbation of either anterior or posterior segment eye disease, and there was a marked improvement in ocular status in the group as a whole. There was a significant decrease in onchocercal involvement which was maintained for at least 3 years. Annual treatment with ivermectin can be used safely in patients with severe ocular disease and is beneficial over a prolonged period of time.

Author Notes

Copyright:
Copyright © 1989 by The American Society of Tropical Medicine and Hygiene 1989
Published Online:
May 1989
Cover The American Journal of Tropical Medicine and Hygiene
The American Journal of Tropical Medicine and Hygiene
Print ISSN:
0002-9637
Past two years Past Year Past 30 Days
Abstract Views 591 437 20
Full Text Views 7 4 0
PDF Downloads 11 5 0
 

 

 

 
 
Affiliate Membership Banner
 
 
Research for Health Information Banner
 
 
CLOCKSS
 
 
 
Society Publishers Coalition Banner
Save